My Treatment Approach: Navigating First-Line Treatment Options in Locally Advanced and Metastatic Urothelial Cancer - Episode 2

Single-Agent Immune Therapy in UC: The Need for More

Thomas Powles, MBBS, MRCP, MD, discusses how different trials have been used to study urothelial cancer (UC) treatments, including DANUBE, IMvigor130, and KEYNOTE-361, all of which are frontline, randomized, phase 3 studies that were unsuccessful. A trial that had better results involved nivolumab plus gemcitabine/cisplatin, due to patients being in better physical condition to withstand chemotherapy.

EP. 1: Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case
Now Viewing
EP. 2: Single-Agent Immune Therapy in UC: The Need for More